Cargando…

Sustained activity of novel THIOMAB antibody-antibiotic conjugate against Staphylococcus aureus in a mouse model: Longitudinal pharmacodynamic assessment by bioluminescence imaging

Staphylococcus aureus (S. aureus) infections are a leading cause of death by an infectious agent. Survival within host phagocytic cells is one mechanism by which S. aureus evades antibiotic treatment. A novel THIOMAB(™) antibody-antibiotic conjugate (TAC) strategy was developed to kill S. aureus int...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Chenguang, Cai, Hao, Baruch, Amos, Lewin-Koh, Nicholas, Yang, Meng, Guo, Fengxun, Xu, Deming, Deng, Rong, Hazenbos, Wouter, Kamath, Amrita V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818770/ https://www.ncbi.nlm.nih.gov/pubmed/31661493 http://dx.doi.org/10.1371/journal.pone.0224096

Ejemplares similares

Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus in mice
por: Zhou, Chenguang, et al.
Publicado: (2016)

A homogeneous high-DAR antibody–drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides
por: Zacharias, Neelie, et al.
Publicado: (2022)

1305. Comparison of Pharmacokinetics of DSTA4637S, a novel THIOMAB(TM) Antibody-Antibiotic Conjugate, in Patients with Staphylococcus aureus Bacteremia Receiving Standard-of-Care Antibiotics with Pharmacokinetics in Healthy Volunteers
por: Rymut, Sharon M, et al.
Publicado: (2020)

Staphylococcus aureus type I signal peptidase: essential or not essential, that’s the question
por: Hazenbos, Wouter L., et al.
Publicado: (2017)

Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB–siRNA conjugates
por: Cuellar, Trinna L., et al.
Publicado: (2015)

Sustained Circulating Bacterial Deoxyribonucleic Acid Is Associated With Complicated Staphylococcus aureus Bacteremia
por: Gutierrez, Johnny, et al.
Publicado: (2019)

Stably Luminescent Staphylococcus aureus Clinical Strains for Use in Bioluminescent Imaging
por: Plaut, Roger D., et al.
Publicado: (2013)

Pharmacodynamics, Population Dynamics, and the Evolution of Persistence in Staphylococcus aureus
por: Johnson, Paul J. T., et al.
Publicado: (2013)

Antimicrobial pharmacodynamics of vancomycin and disulfiram (Antabuse®) in Staphylococcus aureus
por: Chavva, Hasitha, et al.
Publicado: (2023)

167. A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple-ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Patients with staphylococcus Aureus Bacteremia Receiving Standard-of-care Antibiotics
por: Lim, Jeremy, et al.
Publicado: (2020)

Impact of a Novel Anticoccidial Analogue on Systemic Staphylococcus aureus Infection in a Bioluminescent Mouse Model
por: Nguyen, Hang Thi, et al.
Publicado: (2022)

Effects of isosorbide mononitrate loaded nanoparticles conjugated with anti-Staphylococcus aureus α-toxin on Staphylococcus aureus biofilms
por: Zhang, Yaqian, et al.
Publicado: (2020)

Synergy between Vancomycin and Nafcillin against Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model
por: Leonard, Steven N.
Publicado: (2012)

Dose Assessment of Cefquinome by Pharmacokinetic/Pharmacodynamic Modeling in Mouse Model of Staphylococcus aureus Mastitis
por: Yu, Yang, et al.
Publicado: (2016)

Resistance Evolution Against Antimicrobial Peptides in Staphylococcus aureus Alters Pharmacodynamics Beyond the MIC
por: El Shazely, Baydaa, et al.
Publicado: (2020)

1507. Pharmacodynamic Target Attainment of Daptomycin Against Staphylococcus aureus for Treatment of Pediatric Osteomyelitis
por: Stimes, Grant, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-Resistant Staphylococcus aureus
por: Rox, Katharina, et al.
Publicado: (2022)

Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae
por: Wicha, Wolfgang W, et al.
Publicado: (2019)

Pharmacodynamic Functions of Synthetic Derivatives for Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) and Mycobacterium tuberculosis
por: Dinarvand, Mojdeh, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Fungal Defensin NZX Against Staphylococcus aureus-Induced Mouse Peritonitis Model
por: Zheng, Xueling, et al.
Publicado: (2022)

973. Pharmacokinetic/Pharmacodynamic Evaluation and Dose Optimization of Daptomycin in Pediatric Patients with Staphylococcus aureus Bacteremia
por: Olney, Katie B, et al.
Publicado: (2023)

Structural investigation of human S. aureus-targeting antibodies that bind wall teichoic acid
por: Fong, Rina, et al.
Publicado: (2018)

Conjugated Dienoic Acid Peroxides as Substrates in Chaetopterus Bioluminescence System
por: Zagitova, Renata I., et al.
Publicado: (2023)

Complete Genome Sequences of Bioluminescent Staphylococcus aureus Strains Xen31 and Xen36, Derived from Two Clinical Isolates
por: Blaise, Océane, et al.
Publicado: (2023)

Molecular Cloning, Expression and Peroxidase Conjugation of Staphylococcus aureus Protein A
por: Seyfi Abad Shapouri, Masoud Reza, et al.
Publicado: (2016)

In Vitro Antibacterial Activity of Unconjugated and Conjugated Bile Salts on Staphylococcus aureus
por: Sannasiddappa, Thippeswamy H., et al.
Publicado: (2017)

In Vivo Pharmacokinetics/Pharmacodynamics of Cefquinome in an Experimental Mouse Model of Staphylococcus Aureus Mastitis following Intramammary Infusion
por: Yu, Yang, et al.
Publicado: (2016)

Pharmacokinetic/Pharmacodynamic Correlation of Cefquinome Against Experimental Catheter-Associated Biofilm Infection Due to Staphylococcus aureus
por: Zhou, Yu-Feng, et al.
Publicado: (2016)

Prognostic Power of Pathogen Cell-Free DNA in Staphylococcus aureus Bacteremia
por: Guimaraes, Alessander O, et al.
Publicado: (2019)

Once-Daily Gentamicin Administration for Community-Associated Methicillin Resistant Staphylococcus aureus in an in vitro Pharmacodynamic Model: Preliminary Reports for the Advantages for Optimizing Pharmacodynamic Index
por: Kim, Sun Woo, et al.
Publicado: (2010)

Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
por: Kamath, Amrita V., et al.
Publicado: (2014)

Challenges and advances in the assessment of the disposition of antibody‐drug conjugates
por: Kamath, Amrita V., et al.
Publicado: (2015)

Rapid single cell detection of Staphylococcus aureus by aptamer-conjugated gold nanoparticles
por: Chang, Yi-Chung, et al.
Publicado: (2013)

Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia
por: Leipold, Douglas D., et al.
Publicado: (2018)

In vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Staphylococcus aureus (SA) in the Murine Thigh Infection Model
por: Lepak, Alexander J, et al.
Publicado: (2017)

395 Impact of vancomycin pharmacokinetic/pharmacodynamic data on clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children
por: Yoo, Reenar, et al.
Publicado: (2014)

Design and pharmacodynamics of recombinant NZ2114 histidine mutants with improved activity against methicillin-resistant Staphylococcus aureus
por: Chen, Huixian, et al.
Publicado: (2017)

Panton-Valentine Leukocidin–producing Staphylococcus aureus
por: Adler, Amos, et al.
Publicado: (2006)

Pharmacodynamics of vancomycin in elderly patients aged 75 years or older with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia
por: Mizokami, Fumihiro, et al.
Publicado: (2013)

Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach
por: Garonzik, Samira M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0kggp31ludgdb7trpmlqbrpuv9